Amplia Therapeutics Ltd. (AU:ATX) has released an update.
Amplia Therapeutics Ltd. has reached a significant benchmark in its ACCENT trial by completing the enrollment of 26 patients for the Phase 2a study of narmafotinib for treating advanced pancreatic cancer. This milestone paves the way for interim efficacy analysis, which if successful, will lead to the recruitment of an additional 24 patients. Narmafotinib, a drug that targets the protein FAK implicated in solid tumors, has shown promise in earlier trials and is now being tested in combination with chemotherapy across 11 clinical sites in Australia and South Korea.
For further insights into AU:ATX stock, check out TipRanks’ Stock Analysis page.
